Alvesco has been approved by the FDA for the maintenance treatment of asthma and as prophylactic therapy in patients over the age of 12. The drug, manufactured by Nycomed, is an inhaled corticosteroid, which inhibits the activity of pro-inflammatory cells and promotes the endogenous production of anti-inflammatory substances. Alvesco has been approved in 45 countries and introduced in 30, with more launches expected this year.
Asthma Risk Increases When Child Had Bronchiolitis
September 1, 2016
Paradoxical Bronchospasm a Rare Unrecognized Phenotype of Patients with COPD, Asthma
October 12, 2021
Air Quality in Nursing Homes Affects Seniors’ Lung Health
March 27, 2015